Journal
STEM CELL RESEARCH & THERAPY
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13287-022-03163-w
Keywords
Immunotherapy; Chimeric antigen receptors; CAR T-cell; CAR-NK cell; CAR-M solid tumors; Hematological malignancies
Ask authors/readers for more resources
Advancements in adoptive cell therapy have brought forth new therapeutic strategies like CAR T-cells, showing promise in hematological malignancies. However, obstacles remain in using CAR T-cell therapy for both solid tumors and hematological malignancies. CAR-NK and CAR-M cell therapies have emerged as solutions to these challenges. Trials are ongoing in different human malignancies worldwide to improve CAR immune cell therapy.
Advancements in adoptive cell therapy over the last four decades have revealed various new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated immune cells that are engineered and administered to eliminate cancer cells. In this context, CAR T-cells have shown significant promise in the treatment of hematological malignancies. However, many obstacles limit the efficacy of CAR T-cell therapy in both solid tumors and hematological malignancies. Consequently, CAR-NK and CAR-M cell therapies have recently emerged as novel therapeutic options for addressing the challenges associated with CAR T-cell therapies. Currently, many CAR immune cell trials are underway in various human malignancies around the world to improve antitumor activity and reduce the toxicity of CAR immune cell therapy. This review will describe the comprehensive literature of recent findings on CAR immune cell therapy in a wide range of human malignancies, as well as the challenges that have emerged in recent years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available